United States -  Biodefense program 

The United States biodefense framework is a multi-agency enterprise designed to shield the nation from biological threats, whether they are naturally occurring (like pandemics), accidental (such as laboratory leaks), or deliberate (biological warfare or bioterrorism). 

According to reports from the U.S. Government Accountability Office (GAO), the biodefense infrastructure is decentralized, spanning over a dozen federal departments, and is unified by a singular national overarching strategy (GAO, 2023).

1. The Core Strategy: The National Biodefense Strategy

The foundational roadmap for the country’s defense is the National Biodefense Strategy and Implementation Plan, originally unveiled in 2018 and comprehensively updated by the White House in October 2022 via National Security Memorandum 15 (NSM-15) (White House / ASPR, 2022).  

According to the Administration for Strategic Preparedness and Response (ASPR), the strategy organizes the "whole-of-government" response into five core pillars:

Goal 1: Risk Awareness & Detection: Building modern "One Health" biosurveillance networks that monitor human, animal, plant, and environmental data to catch emerging pathogens early.  (ASPR)

Goal 2: Prevention: Strengthening laboratory biosecurity and biosafety globally to prevent leaks, tracking dual-use research, and preventing state or non-state actors from acquiring biological weapons.   (ASPR)

Goal 3: Preparedness: Maintaining a strong scientific research base, securing critical medical supply supply chains, and scaling up clinical infrastructure.  

Goal 4: Rapid Response: Executing unified operations during a biological event, deploying counter-measures, and utilizing effective public communication to curb a crisis.  (ASPR)

Goal 5: Recovery: Mitigating cascading economic damage and restoring critical infrastructure, local environments, and communities post-incident.  

2. Key Agencies and Programs

Because biological defense overlaps public health, national security, and agriculture, responsibilities are split across several major pillars:

Department of Health and Human Services (HHS)

HHS acts as the primary coordinator for the interagency strategy (GAO, 2022).  

ASPR (Administration for Strategic Preparedness and Response): Oversees the Strategic National Stockpile (SNS), which stores vaccines, therapeutics, and personal protective equipment (PPE).

BARDA (Biomedical Advanced Research and Development Authority): Funds and manages the advanced development of medical countermeasures (vaccines, drugs, and diagnostics).  

CDC & NIH (NIAID): Lead national epidemiological surveillance and conduct basic biomedical research into infectious diseases.

Department of Defense (DoD)

The military focuses specifically on protecting service members and maintaining combat readiness under biological threat conditions.

Chemical and Biological Defense Program (CBDP): Operates under the 2024 CBDP Enterprise Strategy, prioritizing the rapid scale-up of equipment to counter advanced biological pacing threats from foreign adversaries (DoD, 2024).  

U.S. Department of War

USAMRIID (U.S. Army Medical Research Institute of Infectious Diseases): Headquartered at Fort Detrick, Maryland, this historic facility leads the laboratory research into medical defenses against dangerous weaponizable pathogens 

Department of Homeland Security (DHS)

DHS focuses on domestic threat detection and situational awareness.

BioWatch Program: A localized automated system of environmental aerosol samplers deployed across major U.S. cities designed to flag early signs of an airborne bioterror attack (GAO, 2023). 

NBIC (National Biosurveillance Integration Center): Consolidates biological and health data from various sectors to provide early warning indicators to leadership. 

3. Standards and System Oversight

The safety protocols that govern how the country's high-containment laboratories handle lethal pathogens (like Ebola or Anthrax) are codified across two foundational reference texts published by the federal government:

Biosafety in Microbiological and Biomedical Laboratories (BMBL) (Co-published by CDC and NIH).  

National Institutes of Health Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules.  

A recent comparative analysis by the GAO evaluated U.S. biosafety and biosecurity across 10 key performance metrics, including comprehensive risk assessment, inventory controls, material transport protocols, and emergency response capabilities, noting that the U.S. maintains some of the most strict, tiered laboratory precaution guidelines globally (GAO / CIDRAP, 2026).

Independent Assessments and System Gaps

Independent reviews published by the GAO highlight ongoing systemic friction points within the biodefense infrastructure:  

Coordination & Fragmentation: The GAO has repeatedly warned that because biodefense is splintered among distinct departments (HHS, DoD, DHS, USDA), the U.S. historically faces tracking hurdles, lacks a unified interagency process to monitor lessons learned from multi-agency exercises, and experiences technology modernization delays—particularly regarding next-generation bio-detection hardware (GAO-23-106476). 

References

Administration for Strategic Preparedness and Response (ASPR) / The White House. (2022). National Biodefense Strategy Goals & NSM-15. aspr.hhs.gov  

U.S. Department of Defense (DoD). (2024). Chemical and Biological Defense Program (CBDP) Enterprise Strategy. defense.gov  

U.S. Government Accountability Office (GAO). (2022). Biodefense: Opportunities to Address National Strategy and Programmatic Challenges (GAO-22-105733). gao.gov

U.S. Government Accountability Office (GAO). (2023). Biodefense: Actions Needed to Address Long-Standing Challenges (GAO-23-106476). gao.gov  

Center for Infectious Disease Research and Policy (CIDRAP) / GAO. (2026). Federal report: Biosafety guidance from 9 of 10 selected G20 countries has similar key features as US program (GAO-26-107338). cidrap.umn.edu